Last update 18 Nov 2026

Iadademstat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Trans-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride, ORY 1001, ORY-1001
+ [4]
Target
Action
inhibitors
Mechanism
KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors), Epigenetic drug
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H24Cl2N2
InChIKeyUCINOBZMLCREGM-ISDLZHGDSA-N
CAS Registry1431303-72-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Myelomonocytic LeukemiaPhase 2
United States
14 Aug 2025
MyelofibrosisPhase 2
United States
14 Aug 2025
Polycythemia VeraPhase 2
United States
14 Aug 2025
Primary MyelofibrosisPhase 2
United States
14 Aug 2025
Thrombocythemia, EssentialPhase 2
United States
14 Aug 2025
Extensive stage Small Cell Lung CancerPhase 2
United States
08 Apr 2025
Neuroendocrine CarcinomaPhase 2
United States
21 Dec 2022
Refractory Small Cell Lung CarcinomaPhase 2
United States
21 Dec 2022
Recurrent Lung Small Cell CarcinomaPhase 2
Spain
10 Oct 2018
acute leukemiaPhase 2
Spain
07 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
17
fbptftqiyi(aejjceubsn) = xcozkxokve tflbulmgts (ykcvxmozni )
Positive
12 Dec 2026
fbptftqiyi(aejjceubsn) = irmmcwktpm tflbulmgts (ykcvxmozni )
Phase 1
22
qtmajosqhv(xghstspwwa) = 4 DLTs occurred (in 3 pts, all in DL2): two cases of prolonged Gr4 neutropenia, one Gr4 differentiation syndrome (DS), and one Gr4 C. difficile colitis. The DS resolved with corticosteroids and supportive care. Thus, current DLT rates were 0% for DL1 and 20% for DL2. dgjrycrjsw (oswdhvtqfv )
Positive
12 Dec 2026
Phase 1
43
mzqprddpea(lkfazfgemx) = Based on the PK, target engagement, safety, tolerability, and efficacy observed in the FRIDA study, the DL-1 of iada at 75 ug (5+2) every week is the RP2D for the combination with gilteritinib. tsnohyuixu (yulgdoevtd )
Positive
12 Dec 2026
Phase 1
FLT3mut
23
wobxyblmiq(zyagtsypxa) = kxhstnzlbw jcfwliqofs (aeaskjhpzj )
Positive
12 May 2026
Phase 1
15
lwealvntyr(sqpoyzhsdo) = wsdpcnbplf ubluaqhufu (aivessigzi )
Positive
12 May 2026
Phase 1
10
exajomoffr(crfeburcfk) = zgfjljbnzy ofjoysgyys (dxwdulpcuo )
Positive
09 Dec 2025
Phase 1
8
ejqdpqlneo(wetolstqcg) = rnrjupxolm giztcuhxyj (ywwammjfdo )
Positive
06 Dec 2025
Phase 2
36
apxdchfnws(mxgqokkuxi) = xgbczmkcrh nrhtknlrii (pevdkhesho )
Positive
15 Nov 2022
Phase 2
24
kwzlmqyjxg(tcdilmxxat) = velrergpih gdkegexqjw (urikulhjba )
-
09 Jun 2021
Phase 2
Small Cell Lung Cancer
iada responsive biomarkers
14
Iadademstat + platinum-etoposide
qktfpmqfdw(ywhzyrnvfc) = Iada-PtEt showed high hematotoxicity despite different combination dosing schemes were evaluated, including skipping iada and/or dose reductions zyqlexrnbq (wiulaakpvl )
Positive
17 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free